A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
The purpose of this commentary is to focus on the downside of assumption-driven simulation modeling, the potential creation of a multitude of competing models, the mathematically impossible quality adjusted life year (QALY) and the failure to observe the axioms of fundamental measurement in mapping...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Minnesota Libraries Publishing
2021-10-01
|
| Series: | INNOVATIONS in Pharmacy |
| Subjects: | |
| Online Access: | https://pubs.lib.umn.edu/index.php/innovations/article/view/4390 |
| _version_ | 1818888707173777408 |
|---|---|
| author | Paul C. Langley |
| author_facet | Paul C. Langley |
| author_sort | Paul C. Langley |
| collection | DOAJ |
| description | The purpose of this commentary is to focus on the downside of assumption-driven simulation modeling, the potential creation of a multitude of competing models, the mathematically impossible quality adjusted life year (QALY) and the failure to observe the axioms of fundamental measurement in mapping ordinal EQ-5D-5L preferences from the ordinal Quantitative Myasthenia Gravis (QMG) score. A second aspect of this commentary is to propose standards that should be set for the creation and evaluation of value claims in health technology assessment, in particular need fulfillment quality of life (QoL), that meet the demarcation test to distinguish science from non-science. The result is that the present ICER pricing claims for eculizumab and efgartigimod in myasthenia gravis should not be applied without consideration of more relevant evidence. |
| first_indexed | 2024-12-19T16:57:24Z |
| format | Article |
| id | doaj.art-d7b83b07b71f43c58222455a5e18945b |
| institution | Directory Open Access Journal |
| issn | 2155-0417 |
| language | English |
| last_indexed | 2024-12-19T16:57:24Z |
| publishDate | 2021-10-01 |
| publisher | University of Minnesota Libraries Publishing |
| record_format | Article |
| series | INNOVATIONS in Pharmacy |
| spelling | doaj.art-d7b83b07b71f43c58222455a5e18945b2022-12-21T20:13:22ZengUniversity of Minnesota Libraries PublishingINNOVATIONS in Pharmacy2155-04172021-10-0112410.24926/iip.v12i4.4390A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia GravisPaul C. Langley0University of MinnesotaThe purpose of this commentary is to focus on the downside of assumption-driven simulation modeling, the potential creation of a multitude of competing models, the mathematically impossible quality adjusted life year (QALY) and the failure to observe the axioms of fundamental measurement in mapping ordinal EQ-5D-5L preferences from the ordinal Quantitative Myasthenia Gravis (QMG) score. A second aspect of this commentary is to propose standards that should be set for the creation and evaluation of value claims in health technology assessment, in particular need fulfillment quality of life (QoL), that meet the demarcation test to distinguish science from non-science. The result is that the present ICER pricing claims for eculizumab and efgartigimod in myasthenia gravis should not be applied without consideration of more relevant evidence.https://pubs.lib.umn.edu/index.php/innovations/article/view/4390ICER, myasthenia gravis claims, pseudoscience, value claims, N-QOL |
| spellingShingle | Paul C. Langley A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis INNOVATIONS in Pharmacy ICER, myasthenia gravis claims, pseudoscience, value claims, N-QOL |
| title | A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis |
| title_full | A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis |
| title_fullStr | A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis |
| title_full_unstemmed | A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis |
| title_short | A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis |
| title_sort | critical examination for the pricing of eculizumab and efgartigimod in myasthenia gravis |
| topic | ICER, myasthenia gravis claims, pseudoscience, value claims, N-QOL |
| url | https://pubs.lib.umn.edu/index.php/innovations/article/view/4390 |
| work_keys_str_mv | AT paulclangley acriticalexaminationforthepricingofeculizumabandefgartigimodinmyastheniagravis AT paulclangley criticalexaminationforthepricingofeculizumabandefgartigimodinmyastheniagravis |